Viatris Raises Full-Year Revenue Guidance Despite Third-Quarter Net Loss
Viatris lifted its full-year 2026 revenue guidance following third-quarter sales of US$3,749.5 million, maintained its quarterly dividend, and faced a legal battle over South African drug tenders.
Viatris Inc. posted third-quarter 2026 revenue of US$3,749.5 million alongside a net loss of US$325.3 million. Following the report, the drugmaker slightly increased its full-year 2026 revenue guidance. The company also affirmed a US$0.12 quarterly dividend that was originally declared in early November, signaling a continued focus on cash discipline and shareholder returns.
On the operational front, Viatris recently carried out a voluntary Class III recall of specific Telmisartan and Amlodipine tablets. The company is also managing manufacturing remediation at sites in Indore and Nashik. According to analysts cited by Simply Wall St, these plant remediation efforts are expected to reduce second-half 2026 revenue by US$100 million to US$150 million.
The operational updates follow a separate legal challenge in South Africa. Viatris filed papers to appeal an October 20 court ruling that canceled its share of a state HIV drug supply tender. The scrapped portion awarded to Viatris was valued at R1.67bn out of an overall R12.2bn contract for combination pills. The court determined Viatris should have been disqualified because its manufacturing license had expired when bidding closed, while Viatris argued that it held a valid import license and had been awaiting regulatory renewal.
Stock performance has shown strong momentum leading up to these updates. Yahoo Finance reported that the equity climbed 16.8% over the past month and hit a 52-week peak of $20.53, supported by third-quarter adjusted earnings of $0.71 per share that beat the $0.64 consensus estimate. On November 12, 2026, shares traded at EUR 19.11 during the European session on Lang & Schwarz.
Analysts remain divided over future expectations. Simply Wall St noted that its consensus framework projects revenue of US$15.9b and earnings of US$704.2 million by 2029, even as valuation models suggest a 5% downside from current pricing. Meanwhile, Zacks Investment Research assigned the stock a Zacks Rank of #2 (Buy), citing earnings revisions and a forward price-to-earnings multiple of 8X.